NCT05171062View on ClinicalTrials.gov

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

bexmarilimab (FP-1305)

standard 3+3 dose escalation trial of bexmarilimab (FP-1305)

DRUG

Pembrolizumab

Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts

Trial Locations (1)

78229

Mays Cancer Center, UT Health San Antonio, San Antonio

Sponsors

Collaborators (1)

Faron Pharmaceuticals Ltd
All Listed Sponsors
collaborator

Faron Pharmaceuticals Ltd

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT05171062 - Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter